If you are struggling with depression, you are not alone. Our team is here to guide you toward innovative and effective mental health solutions that work when other treatments have not.
Spravato is an empowering way to improve mental health for those who have not had success with traditional treatments. Administered as a nasal spray, Spravato contains esketamine, which has transformative mood-balancing properties that reduce symptoms of depression and suicidal ideation. Our dedicated team is here to help you understand what you can expect from Spravato in Fairfax.
Your comfort during sessions is our priority, which is why we allow you to have control over the environment in which you receive your Spravato treatment. Some patients prefer solitude during their sessions. For these patients, we offer private treatment rooms. For those who prefer to be in the company of others, we also have shared rooms available.
Our practice consists of a team of highly-trained, board-certified mental health providers of all ages and backgrounds. We understand that certain patients may have preferences when it comes to who they are treated by, and we house a diverse group of expert clinicians to ensure we are able to pair you with a practitioner you feel comfortable with. If you have preferences as to your clinician’s age, gender, race, or any other demographics, please do not hesitate to let us know.
We accept most major commercial insurance companies. Spravato at our practice is currently covered by Medicare, Anthem, CareFirst PPO, CareFirst HMO, United Behavioral Health, Cigna, Aetna, Humana Tricare Military, and Optima. This allows for widespread accessibility of this innovative and effective depression treatment.
At Neuropsych Wellness Center, we understand that everyone’s mental health is different, and there is no one size fits all treatment. For this reason, your treatment plan will reflect your unique needs. While Spravato is best administered on a phase-based dosing schedule, we will adjust the timing of these doses to your individual schedule. We will also monitor your progress throughout sessions to determine your frequency of sessions as you complete your initial phase and begin to taper into maintenance doses.
The best way to know how our clinicians can best serve your individual mental health needs is by having a consultation before beginning Spravato treatments. Fairfax clients interested in Spravato should schedule an initial visit at our office, where one of our licensed clinicians will meet with you to discuss your medical and psychiatric history, any current medications you take or treatments you’ve tried, and mental health goals. We can then determine the best plan of care to meet your needs.
We want you to leave this initial consultation feeling excited and prepared for your upcoming journey toward wellness. If you have any questions or concerns about Spravato or your treatment plan, please do not hesitate to discuss this during your first visit or at any point throughout the treatment process.
Spravato (esketamine) is lifesaving for people with severe depression who do not respond to other depression treatments. About 30 to 40% of patients with depression fail to respond to first-line treatments including oral antidepressant medications of all classes (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), etc.) and/or psychotherapy. We can offer Spravato treatment for patients whose depression has not responded to other therapies, described as the “Breakthrough in Depression Treatment in 50 Years.” Spravato is now an FDA-approved treatment. NeuroPsych Wellness Center, PC is proud to have helped prove the efficacy of this breakthrough treatment and to be one of the first to use the newly available groundbreaking treatment.
Our experience is unparalleled as our clinicians administer treatment and monitor patients not technicians. Spravato is the new brand name for esketamine that comes in ready to use nasal spray. It was approved by the FDA in March 2019 for patients with treatment resistant depression, in conjunction with an oral antidepressant. The FDA requires that Spravato treatment takes place only at approved treatment centers. By law, it cannot be prescribed for home use. The treatment is done as an outpatient in the privacy of our offices. The reason antidepressants may not work for everyone is that they target just a few of the brain’s chemical transmitter systems, such as serotonin, norepinephrine, and dopamine.
Spravato is NMDA receptor antagonist for treatment resistant depression. NMDA receptors modulate glutamate. Spravato treatment at NeuroPsych Wellness Center, PC is covered by your insurance. Spravato treatment at our clinic is provided and monitored by Clinicians not technicians.
SPRAVATO® (esketamine) CIII nasal spray is the S-enantiomer of racemic ketamine. SPRAVATO® is an FDA-approved nasal spray for treatment-resistant depression (TRD) and major depressive disorder (MDD) with acute suicidal ideation or behavior (MDSI). Ketamine has not been approved by the FDA to treat depression. Both SPRAVATO® and ketamine are Schedule III controlled substances under the U.S. Controlled Substances Act.
There are no samples of SPRAVATO® available — in accordance with federal guidelines — which prohibit the distribution of samples of class III medications.
SPRAVATO® should be administered in conjunction with an oral antidepressant (AD). In TRD, the new open-label oral AD initiated during Study 1 (short-term) was an SSRI in 32% of patients and an SNRI in 68% of patients. In MDSI trials for adults with MDSI, all patients received comprehensive standard-of-care treatment, including an initial inpatient hospitalization and a newly initiated or optimized oral AD therapy as determined by the investigator.
SSRI=selective serotonin reuptake inhibitor.
SNRI=serotonin and norepinephrine reuptake inhibitor.
The cost of SPRAVATO® to your patients is dependent on their insurance plan. SPRAVATO with Me offers access and affordability options for your patients, depending on their plan.
SPRAVATO® is only administered in a medically supervised healthcare setting that is certified under the SPRAVATO® REMS. SPRAVATO® is not to be delivered directly to patients.
SPRAVATO® is a nasal spray that is administered under the supervision of a healthcare provider. Certified SPRAVATO® treatment centers will need to provide the infrastructure and operational support to prepare and monitor patients during self-administration and prior to release from the treatment center.
If you are interested in establishing your practice as a treatment center for SPRAVATO®, you must enroll in the SPRAVATO® REMS and become certified.
To learn more about REMS certification, visit www.neuropsych4u.com or call 703-865-8686.
If a patient misses treatment sessions, provided there is no worsening of their depressive symptoms, the patient should continue the current dosing schedule.
For patients who miss treatment sessions during maintenance treatment and have worsening of depression symptoms, per clinical judgment, consider returning to the previous dosing schedule (if doses missed during weekly dosing, revert to twice-weekly dosing).
No, under the REMS, SPRAVATO® must be administered in a certified healthcare setting. Due to the possibility of delayed or prolonged sedation or dissociation in some cases, patients should be monitored by a healthcare provider for at least 2 hours following each treatment session, or until the clinician determines the patient is safe to leave.
SPRAVATO® is also administered under REMS due to the potential for abuse and misuse. Consider the risks and benefits of prescribing SPRAVATO® prior to using it in patients at higher risk of abuse. Monitor patients for signs and symptoms of abuse and misuse.
The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®.
Caution patients that SPRAVATO® may impair their ability to drive or operate machinery. Instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.
Spravato is an empowering way to take control of your mental health and improve your quality of life. This innovative medication offers profound depression relief for eligible candidates. If you have tried traditional treatments like antidepressants without success, you may be a candidate. Contact us today to schedule your initial consultation for Spravato in Fairfax.
Induction Phase Weeks 1 to 4:
Day 1 starting dose: 56 mg Administer twice per week
Subsequent doses: 56 mg or 84 mg individualized to each patient.
Maintenance Phase Weeks 5 to 8:
Administer once weekly 56 mg or 84 mg.
Week 9 and after:
Administer every 2 weeks or once weekly 56 mg or 84 mg.
Dosing frequency is individualized to each patient.
It’s important for each patient to continue their treatment with their treating Psychiatrist and Therapist while receiving Spravato Treatment for better results. Our treatment team will co-ordinate your treatment plan about Spravato with your Psychiatrist and Psychotherapist ongoing.
Join our newsletter to receive updates. We respect your privacy and do not share our mailing list.
Copyright © NeuroPsych Wellness Center, 2026. All Rights Reserved.